Cargando…

Progressive decline of glucocerebrosidase in aging and Parkinson's disease

The principal risk factor for developing most adult onset neurodegenerative diseases is aging, with incidence rising significantly after age 50. Despite research efforts, the causes of Parkinson's disease (PD) remain unknown. As neurons age, they show signs of diminished lysosomal and mitochond...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocha, Emily M, Smith, Gaynor A, Park, Eric, Cao, Hongmei, Brown, Eilish, Hallett, Penelope, Isacson, Ole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402088/ https://www.ncbi.nlm.nih.gov/pubmed/25909088 http://dx.doi.org/10.1002/acn3.177

Ejemplares similares

Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice
por: Rocha, Emily M., et al.
Publicado: (2015)

Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain
por: Hallett, Penelope J., et al.
Publicado: (2018)

Fibroblasts from idiopathic Parkinson’s disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2
por: Thomas, Ria, et al.
Publicado: (2021)

Novel pathogenic mutations in the glucocerebrosidase locus
por: Duran, Raquel, et al.
Publicado: (2012)

Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease
por: Hallett, Penelope J., et al.
Publicado: (2019)

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
por: Huebecker, Mylene, et al.
Publicado: (2019)

Parkinsonism Associated with Glucocerebrosidase Mutation
por: Sunwoo, Mun-Kyung, et al.
Publicado: (2011)

Glucocerebrosidase mutations in primary parkinsonism
por: Asselta, Rosanna, et al.
Publicado: (2014)

Glucocerebrosidase mutations and Parkinson disease
por: Vieira, Sophia R. L., et al.
Publicado: (2022)

Correction to: Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
por: Huebecker, Mylene, et al.
Publicado: (2020)

A Nurr1 Agonist Causes Neuroprotection in a Parkinson’s Disease Lesion Model Primed with the Toll-Like Receptor 3 dsRNA Inflammatory Stimulant Poly(I:C)
por: Smith, Gaynor A., et al.
Publicado: (2015)

Glucocerebrosidase and its relevance to Parkinson disease
por: Do, Jenny, et al.
Publicado: (2019)

Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency
por: Gatto, Emilia M., et al.
Publicado: (2019)

Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease
por: Davies, Sian E., et al.
Publicado: (2014)

Advantages and Recent Developments of Autologous Cell Therapy for Parkinson’s Disease Patients
por: Osborn, Teresia M., et al.
Publicado: (2020)

Glucocerebrosidase Involvement in Parkinson Disease and Other Synucleinopathies
por: Almeida, Maria do Rosário
Publicado: (2012)

The relationship between glucocerebrosidase mutations and Parkinson disease
por: Migdalska‐Richards, Anna, et al.
Publicado: (2016)

Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients
por: Alcalay, Roy N., et al.
Publicado: (2020)

Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease
por: Isacson, Ole, et al.
Publicado: (2019)

Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease
por: Wallom, Kerri-Lee, et al.
Publicado: (2021)

Association of CSF Glucocerebrosidase Activity With the Risk of Incident Dementia in Patients With Parkinson Disease
por: Oftedal, Linn, et al.
Publicado: (2023)

SCARB2 variants and glucocerebrosidase activity in Parkinson’s disease
por: Alcalay, Roy N, et al.
Publicado: (2016)

Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains
por: Gegg, Matthew E, et al.
Publicado: (2012)

Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland
por: Olszewska, Diana A., et al.
Publicado: (2020)

Gait asymmetry in glucocerebrosidase mutation carriers with Parkinson’s disease
por: Gera, Anjali, et al.
Publicado: (2020)

Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
por: Filippi, Massimo, et al.
Publicado: (2022)

Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity
por: Omer, Nurit, et al.
Publicado: (2021)

Biochemical consequences of glucocerebrosidase 1 mutations in Parkinson’s disease
por: Yoon, Jeong Hyun, et al.
Publicado: (2023)

Acyl-Ghrelin Attenuates Neurochemical and Motor Deficits in the 6-OHDA Model of Parkinson’s Disease
por: Rees, Daniel, et al.
Publicado: (2022)

Cell type-specific lipid storage changes in Parkinson’s disease patient brains are recapitulated by experimental glycolipid disturbance
por: Brekk, Oeystein Roed, et al.
Publicado: (2020)

Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age
por: Brekk, Oeystein R., et al.
Publicado: (2018)

Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson’s Disease
por: Gruschus, James M.
Publicado: (2015)

Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden
por: Ran, Caroline, et al.
Publicado: (2016)

Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease
por: Atashrazm, Farzaneh, et al.
Publicado: (2018)

Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease
por: Avenali, Micol, et al.
Publicado: (2020)

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
por: Galper, Jasmin, et al.
Publicado: (2021)

Patients’ experiences of Parkinson’s disease: a qualitative study in glucocerebrosidase and idiopathic Parkinson’s disease
por: Bonner, N., et al.
Publicado: (2020)

Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
por: McMahon, Benjamin, et al.
Publicado: (2016)

Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson’s disease
por: Rockenstein, Edward, et al.
Publicado: (2016)

Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson’s disease
por: Leyns, Cheryl E. G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9p1nmte739t2buddncib302rm6